Efficacy and safety of neoadjuvant pyrotinib plus docetaxel/liposomal doxorubicin/cyclophosphamide for HER2-positive breast cancer

被引：0
|
作者：
Chunyu Tian
Minghui Wang
Hancheng Liu
Jianping Liu
Mengze Xu
Lihui Ma
机构：
[1] Affiliated Hospital of Chengde Medical University,Department of Breast Surgery
[2] Chengde Medical University,School of Nursing
来源：
Irish Journal of Medical Science (1971 -) | 2023年 / 192卷 / 3期
关键词：
HER2; breast cancer; Neoadjuvant therapy; Pathological response; Pyrotinib; TAC;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1041 / 1049
页数：8
相关论文
共 50 条
  • [1] Efficacy and safety of neoadjuvant pyrotinib plus docetaxel/liposomal doxorubicin/cyclophosphamide for HER2-positive breast cancer
    Tian, Chunyu
    Wang, Minghui
    Liu, Hancheng
    Liu, Jianping
    Xu, Mengze
    Ma, Lihui
    IRISH JOURNAL OF MEDICAL SCIENCE, 2023, 192 (03) : 1041 - 1049
  • [2] The efficacy and safety of epirubicin and cyclophosphamide combined with pyrotinib in neoadjuvant treatment for HER2-positive breast cancer: A real-world study
    Li, Fu
    Liang, Yimin
    Luo, Ming
    Shen, Jiayue
    Zhou, Taosheng
    Liang, Yajing
    Tang, Xiaoqi
    Yuan, Huiming
    Zeng, Jian
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [3] Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for HER2-positive breast cancer: a prospective cohort study
    Liu, Lu
    Zhu, Mingzhi
    Wang, Yanyan
    Li, Muhan
    Gu, Yuanting
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2023, 21 (01)
  • [4] Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for HER2-positive breast cancer: a prospective cohort study
    Lu Liu
    Mingzhi Zhu
    Yanyan Wang
    Muhan Li
    Yuanting Gu
    World Journal of Surgical Oncology, 21
  • [5] Neoadjuvant pyrotinib plus nab-paclitaxel, doxorubicin, and cyclophosphamide for HER2-positive locally advanced breast cancer: a retrospective case-series study
    Yao, De-Shun
    Wang, Wei
    Chang, Jin-Yi
    Zhang, Yang
    Zhang, Hui-Wen
    Xu, Jin-Xia
    Cai, Hai-Feng
    GLAND SURGERY, 2021, 10 (12) : 3362 - 3368
  • [6] Docetaxel, cyclophosphamide, and trastuzumab as neoadjuvant chemotherapy for HER2-positive primary breast cancer
    Nakatsukasa, Katsuhiko
    Koyama, Hiroshi
    Oouchi, Yoshimi
    Imanishi, Seiichi
    Mizuta, Naruhiko
    Sakaguchi, Kouichi
    Fujita, Yoshifumi
    Imai, Aya
    Okamoto, Akiko
    Hamaoka, Asako
    Soushi, Mari
    Fujiwara, Ikuya
    Kotani, Tatsuya
    Matsuda, Takayuki
    Fukuda, Kenichirou
    Morita, Midori
    Kawakami, Sadao
    Kadotani, Yayoi
    Konishi, Eiichi
    Yanagisawa, Akio
    Goto, Mariko
    Yamada, Kei
    Taguchi, Tetsuya
    BREAST CANCER, 2017, 24 (01) : 92 - 97
  • [7] Clinical observation of neoadjuvant chemotherapy with pyrotinib plus trastuzumab in HER2-positive breast cancer: a cohort study
    Li, Qi
    Wang, Yanyan
    Zhu, Mingzhi
    Gu, Yuanting
    Tang, Yajing
    GLAND SURGERY, 2021, 10 (12) : 3389 - 3402
  • [8] Efficacy and Safety of Radiotherapy Combined with Pyrotinib in the Treatment of HER2-Positive Breast Cancer with Brain Metastases
    Huang, Jie
    Zhu, Wenqiang
    Duan, Qiangzhi
    Zhu, Chaomang
    Shi, Xueling
    Zhao, Hongyu
    Cai, Peng
    Li, Duojie
    BREAST CANCER-TARGETS AND THERAPY, 2023, 15 : 841 - 853
  • [9] Docetaxel, cyclophosphamide, and trastuzumab as neoadjuvant chemotherapy for HER2-positive primary breast cancer
    Katsuhiko Nakatsukasa
    Hiroshi Koyama
    Yoshimi Oouchi
    Seiichi Imanishi
    Naruhiko Mizuta
    Kouichi Sakaguchi
    Yoshifumi Fujita
    Aya Imai
    Akiko Okamoto
    Asako Hamaoka
    Mari Soushi
    Ikuya Fujiwara
    Tatsuya Kotani
    Takayuki Matsuda
    Kenichirou Fukuda
    Midori Morita
    Sadao Kawakami
    Yayoi Kadotani
    Eiichi Konishi
    Akio Yanagisawa
    Mariko Goto
    Kei Yamada
    Tetsuya Taguchi
    Breast Cancer, 2017, 24 : 92 - 97
  • [10] Pyrotinib as a therapeutic for HER2-positive breast cancer
    Kioutchoukova, Ivelina
    Lucke-Wold, Brandon P.
    TRANSLATIONAL CANCER RESEARCH, 2023, 12 (06) : 1376 - 1379
12345